Aeterna Zentaris to Announce Third Quarter 2016 Financial and Operating Results on November 8, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) will announce its third quarter 2016 financial and operating results after market close on Tuesday, November 8, 2016. The Company will host a conference call and webcast to discuss these results on Wednesday, November 9, 2016 at 8:30 a.m. Eastern Time. During the call, management will also provide an update on the status and progress related to the Company’s two pivotal phase 3 programs for Macrilen™ and Zoptrex™.

Participants may access the live webcast via the Company's website at www.aezsinc.com, or by telephone using the following number: 201-689-8029, Confirmation #13646681. A replay of the webcast will also be available on the Company’s website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds: Macrilen™ and Zoptrex™. The focus of our business development efforts is the acquisition or license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005078/en/

Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice [e-mail]